In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)
Shio-Shin Jean,1,2 Min-Chi Lu,3 Zhi-Yuan Shi,4 Shu-Hui Tseng,5 Ting-Shu Wu,6 Po-Liang Lu,7 Pei-Lan Shao,8 Wen-Chien Ko,9 Fu-Der Wang,10,11 Po-Ren Hsueh12,13 1Department of Emergency Medicine and Emergency and Critical Care Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; 2Depa...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-10-01
|
Series: | Infection and Drug Resistance |
Subjects: | |
Online Access: | https://www.dovepress.com/in-vitro-activity-of-ceftazidimendashavibactam-ceftolozanendashtazobac-peer-reviewed-article-IDR |
id |
doaj-c10a4401cfed4be18e2b445ba2ba7151 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jean SS Lu MC Shi ZY Tseng SH Wu TS Lu PL Shao PL Ko WC Wang FD Hsueh PR |
spellingShingle |
Jean SS Lu MC Shi ZY Tseng SH Wu TS Lu PL Shao PL Ko WC Wang FD Hsueh PR In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) Infection and Drug Resistance Enterobacteriaceae Neisseria gonorrhoeae extended-spectrum β-lactamases carbapenemase ceftolozane-tazobactam ceftazidime-avibactam |
author_facet |
Jean SS Lu MC Shi ZY Tseng SH Wu TS Lu PL Shao PL Ko WC Wang FD Hsueh PR |
author_sort |
Jean SS |
title |
In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) |
title_short |
In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) |
title_full |
In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) |
title_fullStr |
In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) |
title_full_unstemmed |
In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) |
title_sort |
in vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important gram-negative bacilli: results from the 2017 surveillance of multicenter antimicrobial resistance in taiwan (smart) |
publisher |
Dove Medical Press |
series |
Infection and Drug Resistance |
issn |
1178-6973 |
publishDate |
2018-10-01 |
description |
Shio-Shin Jean,1,2 Min-Chi Lu,3 Zhi-Yuan Shi,4 Shu-Hui Tseng,5 Ting-Shu Wu,6 Po-Liang Lu,7 Pei-Lan Shao,8 Wen-Chien Ko,9 Fu-Der Wang,10,11 Po-Ren Hsueh12,13 1Department of Emergency Medicine and Emergency and Critical Care Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; 2Department of Emergency, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; 3Department of Microbiology and Immunology, School of Medicine, China Medical University, Taichung, Taiwan; 4Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; 5Center for Disease Control and Prevention, Ministry of Health and Welfare, Taiwan; 6Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan; 7Department of Internal Medicine, Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; 8Department of Pediatrics, Hsin-Chu Branch, National Taiwan University Hospital, Hsin-Chu, Taiwan; 9Department of Internal Medicine, National Cheng Kung University Medical College and Hospital, Tainan, Taiwan; 10Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; 11School of Medicine, National Yang-Ming University, Taipei, Taiwan; 12Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; 13Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan Objectives: We investigated the in vitro antimicrobial susceptibilities of clinically important Gram-negative bacteria (GNB) from 16 major teaching hospitals in Taiwan in 2017. Materials and methods: Escherichia coli (n=686) and Klebsiella pneumoniae bloodstream isolates (n=673), non-typhoid Salmonella (NTS; n=221) from various sources, Shigella species (n=21) from fecal samples, and Neisseria gonorrhoeae (n=129) from the genitourinary tract were collected. Antibiotic minimum inhibitory concentrations (MICs) were determined using the broth microdilution method. Alleles encoding K. pneumoniae carbapenemases (KPCs), New Delhi metallo-β-lactamases (NDMs), Verona integron-encoded metallo-β-lactamase, imipenemase, OXA-48-like, and mcr-1-5 genes were detected by molecular methods in Enterobacteriaceae isolates. Results: Five (0.7%) E. coli isolates harbored mcr-1 alleles. Twenty-four (3.6%), seven (1.0%), four (0.6%), and one (0.15%) K. pneumoniae isolates contained bla KPC, bla OXA-48-like, mcr-1, and bla NDM, respectively. Three (1.4%) NTS and no Shigella isolates harbored mcr-1 genes. Seventy-one (10.5%) K. pneumoniae isolates displayed non-susceptibility (NS) to carbapenem agent(s). Phenotypically extended-spectrum β-lactamase (ESBL)-producing K. pneumoniae isolates showed significantly higher rates of ertapenem, tigecycline, and ceftolozane–tazobactam (CLZ–TAZ) NS (40.2%, 16.3%, and 71%–80%, respectively) than E. coli isolates exhibiting ESBL phenotypes (5.4%, 0.7%, and 18%–28%, respectively). All phenotypically ESBL-producing E. coli isolates were ceftazidime–avibactam (CAZ–AVB) susceptible. Two (8.3%) KPC-producing K. pneumoniae isolates showed CAZ–AVB NS. Hospital-acquired K. pneumoniae isolates were significantly less susceptible to ertapenem and CLZ–TAZ than hospital-acquired E. coli isolates. Conclusion: Third-generation cephalosporins remain the optimal choice for treating NTS, Shigella, and gonococcal infections in Taiwan. Hospital-acquired and phenotypically ESBL-producing K. pneumoniae are a heavy resistance burden in Taiwan. Keywords: Enterobacteriaceae, Neisseria gonorrhoeae, extended-spectrum β-lactamases, carbapenemase, ceftolozane–tazobactam, ceftazidime–avibactam |
topic |
Enterobacteriaceae Neisseria gonorrhoeae extended-spectrum β-lactamases carbapenemase ceftolozane-tazobactam ceftazidime-avibactam |
url |
https://www.dovepress.com/in-vitro-activity-of-ceftazidimendashavibactam-ceftolozanendashtazobac-peer-reviewed-article-IDR |
work_keys_str_mv |
AT jeanss invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart AT lumc invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart AT shizy invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart AT tsengsh invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart AT wuts invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart AT lupl invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart AT shaopl invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart AT kowc invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart AT wangfd invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart AT hsuehpr invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart |
_version_ |
1725764720263168000 |
spelling |
doaj-c10a4401cfed4be18e2b445ba2ba71512020-11-24T22:23:21ZengDove Medical PressInfection and Drug Resistance1178-69732018-10-01Volume 111983199241828In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)Jean SSLu MCShi ZYTseng SHWu TSLu PLShao PLKo WCWang FDHsueh PRShio-Shin Jean,1,2 Min-Chi Lu,3 Zhi-Yuan Shi,4 Shu-Hui Tseng,5 Ting-Shu Wu,6 Po-Liang Lu,7 Pei-Lan Shao,8 Wen-Chien Ko,9 Fu-Der Wang,10,11 Po-Ren Hsueh12,13 1Department of Emergency Medicine and Emergency and Critical Care Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; 2Department of Emergency, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; 3Department of Microbiology and Immunology, School of Medicine, China Medical University, Taichung, Taiwan; 4Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; 5Center for Disease Control and Prevention, Ministry of Health and Welfare, Taiwan; 6Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan; 7Department of Internal Medicine, Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; 8Department of Pediatrics, Hsin-Chu Branch, National Taiwan University Hospital, Hsin-Chu, Taiwan; 9Department of Internal Medicine, National Cheng Kung University Medical College and Hospital, Tainan, Taiwan; 10Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; 11School of Medicine, National Yang-Ming University, Taipei, Taiwan; 12Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; 13Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan Objectives: We investigated the in vitro antimicrobial susceptibilities of clinically important Gram-negative bacteria (GNB) from 16 major teaching hospitals in Taiwan in 2017. Materials and methods: Escherichia coli (n=686) and Klebsiella pneumoniae bloodstream isolates (n=673), non-typhoid Salmonella (NTS; n=221) from various sources, Shigella species (n=21) from fecal samples, and Neisseria gonorrhoeae (n=129) from the genitourinary tract were collected. Antibiotic minimum inhibitory concentrations (MICs) were determined using the broth microdilution method. Alleles encoding K. pneumoniae carbapenemases (KPCs), New Delhi metallo-β-lactamases (NDMs), Verona integron-encoded metallo-β-lactamase, imipenemase, OXA-48-like, and mcr-1-5 genes were detected by molecular methods in Enterobacteriaceae isolates. Results: Five (0.7%) E. coli isolates harbored mcr-1 alleles. Twenty-four (3.6%), seven (1.0%), four (0.6%), and one (0.15%) K. pneumoniae isolates contained bla KPC, bla OXA-48-like, mcr-1, and bla NDM, respectively. Three (1.4%) NTS and no Shigella isolates harbored mcr-1 genes. Seventy-one (10.5%) K. pneumoniae isolates displayed non-susceptibility (NS) to carbapenem agent(s). Phenotypically extended-spectrum β-lactamase (ESBL)-producing K. pneumoniae isolates showed significantly higher rates of ertapenem, tigecycline, and ceftolozane–tazobactam (CLZ–TAZ) NS (40.2%, 16.3%, and 71%–80%, respectively) than E. coli isolates exhibiting ESBL phenotypes (5.4%, 0.7%, and 18%–28%, respectively). All phenotypically ESBL-producing E. coli isolates were ceftazidime–avibactam (CAZ–AVB) susceptible. Two (8.3%) KPC-producing K. pneumoniae isolates showed CAZ–AVB NS. Hospital-acquired K. pneumoniae isolates were significantly less susceptible to ertapenem and CLZ–TAZ than hospital-acquired E. coli isolates. Conclusion: Third-generation cephalosporins remain the optimal choice for treating NTS, Shigella, and gonococcal infections in Taiwan. Hospital-acquired and phenotypically ESBL-producing K. pneumoniae are a heavy resistance burden in Taiwan. Keywords: Enterobacteriaceae, Neisseria gonorrhoeae, extended-spectrum β-lactamases, carbapenemase, ceftolozane–tazobactam, ceftazidime–avibactamhttps://www.dovepress.com/in-vitro-activity-of-ceftazidimendashavibactam-ceftolozanendashtazobac-peer-reviewed-article-IDREnterobacteriaceaeNeisseria gonorrhoeaeextended-spectrum β-lactamasescarbapenemaseceftolozane-tazobactamceftazidime-avibactam |